产品
编 号：F154082
分子式：C14H12N6O
分子量：280.28
分子式：C14H12N6O
分子量：280.28
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
100mg
560
In-stock
500mg
2304
In-stock
结构图
CAS No: 141505-33-1
产品详情
生物活性：
Levosimendan (Simsndan; OR-1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.
体外研究：
Levosimendan (OR1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. Levosimendan (OR1259) is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic heart failure, and in situations where conventional therapy is not considered adequate. Levosimendan (OR1259) has shown preliminary positive effects in a range of conditions requiring inotropic support, including right ventricular failure, cardiogenic shock, septic shock, and Takotsubo cardiomyopathy. The cardiovascular effects of Levosimendan (OR1259) are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators. Levosimendan (OR1259) might reduce mortality in cardiac surgery and cardiology settings of adult patients.
Levosimendan (Simsndan; OR-1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.
体外研究：
Levosimendan (OR1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. Levosimendan (OR1259) is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic heart failure, and in situations where conventional therapy is not considered adequate. Levosimendan (OR1259) has shown preliminary positive effects in a range of conditions requiring inotropic support, including right ventricular failure, cardiogenic shock, septic shock, and Takotsubo cardiomyopathy. The cardiovascular effects of Levosimendan (OR1259) are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators. Levosimendan (OR1259) might reduce mortality in cardiac surgery and cardiology settings of adult patients.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备